Back

Sacubitril/valsartan promotes cardiac reverse remodeling and preserves renal function in a real-world heart failure and reduced ejection fraction (HFrEF) population

4 December 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Imaging: heart failure Imaging of Heart Failure EACVI Premium Access EuroEcho 2019

9 More presentations in this session

Presentation thumbnail
Panel of experts:.
Presentation thumbnail
The relationship between right ventricle-arterial coupling and cardiac metabolism in pulmonary arterial hypertension - multimodal study.
Doctor R. Kazimierczyk (Bialystok, PL)
Abstract Slides Video
Presentation thumbnail
Left atrial pump function assessed by speckle tracking echocardiography adds important value for the diagnosis of heart failure with preserved ejection fraction
Associate Professor R. Rimbas (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
Early cardiac reverse remodeling in a large cohort of patients with HFrEF treated with Sacubitril/Valsartan
Slides Video
Presentation thumbnail
Recompensation induces distinct changes in myocardial work in patients with acutely decompensated heart failure and reduced vs preserved left ventricular ejection fraction
Doctor C. Morbach (Wuerzburg, DE)
Abstract

Access the full session

Session thumbnail
Imaging: heart failure

The Event

Event poster

EuroEcho 2019

4 December - 7 December 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources